{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:58:46Z","timestamp":1768438726131,"version":"3.49.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Transthyretin (TTR) amyloidosis (ATTR) occurs due to misfolding and aggregation of TTR protein in numerous organs and tissues, resulting in various clinical presentations including cardiomyopathy and polyneuropathy. The pathophysiology of ATTR cardiomyopathy is characterized by TTR deposition in the interstitial space between cardiac myocytes, contributing to microvascular dysfunction and cardiac myocyte injury and necrosis. As the misfolded TTR protein accumulates in cardiac tissue, it results in impaired diastolic function, progressive ventricular wall thickening, and impaired longitudinal systolic function. Understanding the pathophysiology of ATTR cardiomyopathy has allowed for the development of pharmacotherapies that target the disease process, including the identification of a stabilizing TTR gene mutation, threonine119methionine (T119M), that confers resistance towards amyloidogenesis. In 2019, the Food and Drug Administration approved tafamidis for the treatment of ATTR cardiomyopathy due to its ability to stabilize the TTR tetramer and prevent dissociation into monomers that subsequently cause amyloidosis. In 2024, acoramidis was approved for ATTR cardiomyopathy as a novel TTR stabilizer structurally designed to mimic the stabilizing effects of the T119M mutation by binding selectively and with high affinity to TTR, preventing the dissociation of TTR tetramer into monomers and aggregation into amyloid fibrils. In 2025, vutrisiran, a small interfering ribonucleic acid that cleaves TTR messenger RNA and decreases the production of TTR protein, was approved for use in ATTR cardiomyopathy. In their clinical trials, these approved therapies demonstrated significant mortality and morbidity benefits in patients with ATTR cardiomyopathy, including a decrease in cardiovascular events, hospitalizations, and functional status.<\/jats:p>","DOI":"10.1097\/crd.0000000000000985","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:00:30Z","timestamp":1751374830000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Transthyretin Amyloid Cardiomyopathy: A Review of Approved Pharmacotherapies"],"prefix":"10.1097","author":[{"given":"Mohammed","family":"Kallash","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"R2-20250701","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250701","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis.","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"R4-20250701","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review.","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"R5-20250701","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid Nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"key":"R6-20250701","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"R7-20250701","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20250701","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"R9-20250701","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"392","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20250701","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"key":"R11-20250701","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease.","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"R12-20250701","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1038\/s41467-021-27416-z","article-title":"Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.","volume":"12","author":"Slamova","year":"2021","journal-title":"Nat Commun"},{"key":"R13-20250701","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-20250701","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system [published correction appears in J Am Coll Cardiol. 2017 Jun 13;69(23):2882. doi: 10.1016\/j.jacc.2017.05.002.].","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R15-20250701","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev"},{"key":"R16-20250701","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease.","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"key":"R17-20250701","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.","volume":"8","author":"Maurer","year":"2015","journal-title":"Circ Heart Fail"},{"key":"R18-20250701","doi-asserted-by":"crossref","first-page":"e004769","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis.","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R21-20250701","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"R23-20250701","first-page":"30","article-title":"Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis [published correction appears in Heart Int. 2024 Aug 02;18(2):3. doi: 10.17925\/HI.2024.18.2.6.].","volume":"18","author":"Ioannou","year":"2024","journal-title":"Heart Int"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:00:32Z","timestamp":1751374832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000985","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}